Month One Is a Low-Dose Month on Purpose
The first month on a GLP-1 medication is spent entirely at the lowest dose in the schedule, and that is a feature, not a delay. The Wegovy prescribing information starts adults at 0.25 mg of semaglutide once weekly for 4 weeks, then raises the dose every 4 weeks toward the 2.4 mg maintenance dose. Zepbound follows the same rhythm: 2.5 mg of tirzepatide once weekly for 4 weeks, then 5 mg, with further increases possible in 2.5 mg steps. Both labels give the same reason for the slow ramp, reducing the risk of gastrointestinal side effects.
So four injections, one per week, all at a dose the manufacturers themselves do not consider the working dose. Novo Nordisk's dosing guidance even allows your prescriber to hold you at a step for an extra 4 weeks if you are not tolerating it. If you want the background on how these two medications differ, our semaglutide vs tirzepatide comparison covers the molecules, and the eligibility guide covers who qualifies in the first place.
Week by Week: What the First Four Weeks Look Like
The honest week-by-week answer is that the first month follows a pattern set by the dose schedule, not a script your body has agreed to. Individual experience varies a lot. What the table below describes is the structure every patient shares, drawn from the FDA prescribing information for Wegovy and Zepbound, plus the practical decisions that tend to land in each stretch.
| Stretch | Wegovy (semaglutide) | Zepbound (tirzepatide) | What is typically going on |
|---|---|---|---|
| Weeks 1 to 2 | 0.25 mg once weekly | 2.5 mg once weekly | First injections. You learn the pen, pick an injection day, and find out how your stomach reacts. Appetite changes may appear for some people; nausea, if it comes, often shows up in this stretch. |
| Weeks 3 to 4 | 0.25 mg once weekly | 2.5 mg once weekly | Same dose, more routine. Many patients settle into eating smaller portions because larger ones stop feeling good. This is the stretch to build habits: hydration, protein first, an injection-day reminder. |
| End of week 4 | Label moves to 0.5 mg | Label moves to 5 mg | The first escalation decision. Your prescriber decides whether to step up on schedule or hold the current dose longer, which both labels explicitly allow for tolerability. |
Doses and escalation timing are drawn from the FDA prescribing information for Wegovy and Zepbound. Your prescriber's schedule for you takes priority over the default label schedule.
One logistics note from the Wegovy label that saves people real anxiety: the injection can be taken at any time of day, with or without food, and you can move your weekly injection day as long as at least 48 hours separate two doses. Missed-dose rules are specific and worth reading in the prescribing information rather than guessing.
Side Effects: When They Show Up and What Helps
Gastrointestinal side effects are the defining side effect story of month one on a GLP-1, and the timing is not random. The prescribing information for both Wegovy and Zepbound states that the dose-escalation schedule exists to reduce the risk of gastrointestinal adverse reactions, which cluster around starting treatment and raising the dose. Nausea leads the list, followed by vomiting, diarrhea, and constipation. Not everyone gets them. Plenty of people sail through week one and then meet nausea at a dose increase months later.
What helps is mostly unglamorous: smaller meals, eating slowly, stopping when full arrives early, and drinking enough water, since vomiting or diarrhea plus a suppressed appetite is a fast route to dehydration. If a side effect is severe, persistent, or keeps you from keeping fluids down, that is a call to your prescriber, not something to push through. Our full GLP-1 side effects guide covers the complete picture, including the warning signs that need prompt medical attention.
What the Scale Will and Will Not Do
The scale is the least useful measurement you own during your first month on a GLP-1, because you are on the lowest dose the schedule contains. The clinical trials that produced the famous results measured them after 68 to 72 weeks of treatment, most of it at full maintenance doses. Head-to-head data like the trial covered in our Ozempic vs Mounjaro guide ran 72 weeks. Nobody published a month-one leaderboard, and there is a reason for that.
Some people do see early movement, usually because appetite suppression kicks in fast for them. Others see almost nothing and panic. Do not renegotiate your treatment in week three. What month one is actually for is tolerability data: how you handle the medication is the input your prescriber needs for the escalation decision. Weight is a later chapter. If cost is the thing quietly stressing you during this stretch, the GLP-1 cost guide lays out what these medications run with and without coverage.
The End-of-Month Decision
Week four ends with a decision that belongs to your prescriber: step up to the next dose on the label schedule, or hold where you are. The Wegovy prescribing information tells clinicians to consider delaying escalation for 4 weeks if a patient is not tolerating a dose, and Zepbound's label builds in the same at-least-4-weeks spacing between increases. Holding is not failing. It is the schedule working as written.
Come to that conversation with actual information: which side effects you had and when, whether you could eat and drink normally, and any symptom that worried you. If your prescription came through a telehealth program, this is exactly what the follow-up visit is for; our comparison of online GLP-1 programs notes which ones include ongoing clinician check-ins rather than a one-time consult.
Frequently Asked Questions
Four weeks, for both major weight-management GLP-1 medications. The FDA prescribing information for Wegovy starts patients at 0.25 mg once weekly for 4 weeks, and the Zepbound prescribing information starts patients at 2.5 mg once weekly for 4 weeks. Escalation to the next dose happens after that first month, and prescribers can delay an increase if a patient is not tolerating the current dose. Your prescriber sets your actual schedule.
There is no reliable month-one number, and anyone quoting you one is guessing. The first month is spent on the lowest dose in the schedule, and the clinical trials behind these medications measured their headline results after 68 to 72 weeks, not 4. Some people see early movement on the scale, others see very little. The first month is not a fair test of the medication, so judge it later, with your prescriber.
Gastrointestinal side effects, mainly nausea, vomiting, diarrhea, and constipation. The FDA prescribing information for both Wegovy and Zepbound states that the gradual dose-escalation schedule exists specifically to reduce the risk of gastrointestinal adverse reactions, which are reported most often when starting treatment or raising the dose. Contact your prescriber about any side effect that is severe, persistent, or keeps you from staying hydrated.
Generally yes. The Wegovy prescribing information allows the weekly injection day to be changed as long as there are at least 48 hours between doses, and the dose can be taken at any time of day, with or without meals. Check the prescribing information for your specific medication and confirm any schedule change with your prescriber, especially if you have missed a dose.
Starting a GLP-1? Do It With a Clinician in the Loop
The first month goes better with a licensed clinician who reviews your medical history before you start and is reachable when the first side effects or dose questions show up. Licensed online programs provide exactly that, including the prescription itself if treatment is appropriate.
Prescription required. Medical screening and clinician review required. Not all patients will qualify. Affiliate disclosure: this site may earn a referral fee from programs listed.
Compare Online GLP-1 ProgramsSources
The following official sources were used for the dosing schedules, escalation rules, and side effect timing referenced on this page. Always verify against the most current version of each document.
- Wegovy (semaglutide) US Prescribing Information, Novo Nordisk: starting dose, 4-week escalation intervals, tolerability delays, and administration rules.
- Novo Nordisk (novomedlink.com). Wegovy Dosing Information for healthcare professionals.
- Zepbound (tirzepatide) US Prescribing Information, Eli Lilly: 2.5 mg initiation dose, 4-week escalation spacing, and gastrointestinal adverse reaction guidance.